CASE REPORT

Leukemic infiltration in the settings of acute respiratory failure

M. Fayed1,*, T. Evans1 and H. Abdulhaq2

1Pulmonary Critical Care Division, UCSF Fresno, Fresno, CA, USA, 2Hematology Oncology, UCSF Fresno, Fresno, CA, USA

*Correspondence address. Pulmonary Critical Care Division, UCSF Fresno, Fresno, CA, USA. Tel: 559-459-2065; Fax: 559-459-6113; E-mail: mfayed@fresno.ucsf.edu

Abstract

Hematological malignancies need special attention in the intensive care unit (ICU). Leukemia has numerous presentations in the ICU. Most commonly, these patients present with complications of therapy. Infection and neutropenia are major reasons for ICU admission. Pulmonary complications in patients with leukemia are often due to pneumonia, hemorrhage, edema or drug toxicity; however, pulmonary leukemic infiltration is a well-known complication in all types of pneumonia but is not well described in chronic myelomonocytic leukemia. It can contribute to a rapid decline in respiratory status. Distinguishing among infection, pulmonary edema and leukemic infiltrates can be challenging. Characteristic radiological patterns have been described but are still challenging to recognize. Critical care management in these cases can have a large impact, and early intervention could be lifesaving in the appropriate clinical setting.

INTRODUCTION

Pulmonary complications of patients with leukemia are usually caused by infection, hemorrhage or drug toxicity; however, pulmonary leukemic infiltration is an important clinical consideration. Recognizing this complication and applying appropriate interventions may reduce morbidity and mortality.

CASE REPORT

A 62-year-old male with a past medical history of human immunodeficiency virus, who was receiving therapy, had a CD4 count of 641 and had been diagnosed with CMML 2 years ago presented with fatigue and dyspnea on exertion for 1 week. The patient had received different treatment regimens for CMML, including decitabine (5 cycles), ruxolitinib (8-month therapy) and azacitidine (2 cycles). He was recently started on hydroxyurea because of his disease progression and was sent for allogeneic hematopoietic stem cell transplant; however, he was deemed to not be a candidate because of renal dysfunction. The patient was admitted to the hospital for additional work up. He was found to have worsening anemia and thrombocytopenia as well as worsening leukocytosis (62 from 40 K 3 weeks prior to admission). He was diagnosed with autoimmune hemolytic anemia on this admission (positive Coombs test) and was started on prednisone. He received blood products, including several units of packed red blood cell and platelets, to maintain adequate hemoglobin levels and platelet counts. His bone marrow biopsy on admission showed dysmegakaryopoiesis and monoblasts accounting for 14% of the cellularity, which was consistent with CMML.

The patient was started on trimethoprim–sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis, hydroxyurea, IV fluids and allopurinol for tumor lysis syndrome prophylaxis. On Day 5 of admission, radiation oncology was consulted for palliative radiation for refractory and symptomatic splenomegaly because all medical therapy had failed. However, during the course of his admission, his respiratory status deteriorated

Received: June 23, 2019. Revised: September 30, 2019. Accepted: October 12, 2019

© The Author(s) 2019. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
slowly, requiring nasal cannula oxygen, and his X-ray showed
evidence of bilateral infiltrate suggestive of pulmonary edema
(Day 9 of admission). The patient's echocardiogram was normal
2 months prior to his admission, and his current brain natriuretic
peptide level was only 71 pg/ml; however, given his clinical and
radiological status, he was started on IV Lasix. He continued to
deteriorate despite diuresis and required noninvasive positive
pressure ventilation. After pan cultures, he was placed on broad
spectrum IV antibiotics, specifically vancomycin, piperacillin
and tazobactam. He was intubated on Day 10 of admission. His X-
ray and chest computed tomography 1 month prior to admission
showed no evidence of opacity or acute infiltrate, and the
abdominal section showed hepatosplenomegaly (Figs 1, 4 and 5). A chest X-ray on admission (Fig 2) is shown. The chest X-ray
(Fig 3) and chest computed tomography (Fig 6) on Day 8 show
significant interstitial infiltrate. He continued to deteriorate
despite full respiratory support and broad-spectrum antibiotics. His white blood cell (WBC) at the time of admission to the
intensive care unit (ICU) was 124 000, and he expired after 6 h
of mechanical ventilation. The patient experienced refractory
multi-organ failure, and the ICU team was unable to perform
bronchoscopy. Limited lung autopsy was requested, and the
slides are shown (Figs 7 and 8). The final diagnosis made at
autopsy was pulmonary leukemic infiltration associated with
marked pulmonary congestion and hemorrhage. No evidence
of infection was found in these cultures or on autopsy.

**DISCUSSION**
CMML is a malignant hematopoietic stem cell disorder with
clinical and pathological features of both a myeloproliferative

**Figure 1:** Chest X-ray 1 month prior to admission.

**Figure 2:** Chest X-ray on the day of admission; no significant change compared
to his chest X-ray prior to his admission.

**Figure 3:** Chest X-ray on Day 8 of admission; there is diffuse interstitial opacity
in all lung fields bilaterally.

**Figure 4:** Computed tomography 1 month prior to admission; there is evidence
of centrilobular emphysema but no obvious opacity or infiltrates.
Figure 5:Computed tomography 1 month prior to admission; there is evidence of hepatosplenomegaly (white arrow).

Figure 6:Computed tomography at the time of ICU evaluation; there is new onset of interstitial opacity and ground glass opacity (blue arrow) and interlobular thickening (black arrow).

Figure 7: Hematoxylin and eosin slides showed intra-alveolar hemorrhage (blue arrow); the septal capillary blood vessels are distended by a moderately monotonous population of hematolymphoid monocytic cells (black arrow).

Figure 8: Hematolymphoid monocytic cells; these cells are positive for CD 56 in immunohistochemical stain (blue arrow).

The clinical manifestations of CMML are nonspecific, such as recurrent infection, excessive fatigue, dyspnea, petechiae and hemorrhage. CMML symptoms usually result from bone marrow suppression or disease-related complications. Splenomegaly is present in up to 25% of patients with CMML [3], and symptoms related to splenomegaly can occur (e.g. early satiety and abdominal fullness). The most common intrathoracic leukemic manifestation in all types of leukemia is lymphadenopathy [4]. Leukemia can involve lung tissue, pleura and the heart. Leukemic pulmonary infiltration is defined as extravascular collections of leukemic cells in the lung parenchyma without another apparent cause (e.g. infection, hemorrhage or venous congestion) [5]. It usually occurs in the terminal stage of the disease but can also present in different stages of the disease, especially prior to diagnosis.

Pulmonary manifestations of leukemia should be carefully assessed to distinguish different causes that can impact the management plan [6]. Some autopsy studies have shown leukemic pulmonary infiltration in >25% of patients with leukemia [7]. It manifests as a rapid decline in respiratory status, and the peripheral WBC count is usually >100 000. Distinguishing among infection, pulmonary edema and leukemic infiltrate can be challenging. Reports of computed tomography imaging of leukemic infiltrates have described different radiological patterns, but in general, leukemic cells have the tendency to involve the perilymphatic interstitium, producing smooth or nodular thickening of the bronchovascular bundles and interlobular septa [8]. Other radiological patterns include nodular disease, which can be random, centrilobular or prelymphatic [9]. Additionally, ground-glass opacities and air-space consolidation have been described [8–9].

In addition, computed tomography findings are usually not very specific, but the diagnosis can be made after ruling out other disease processes. Bronchoscopy and bronchoalveolar lavage are usually recommended to rule out bleeding and infection. An accurate diagnosis might require lung biopsy.

The most striking finding in this case was interstitial thickening that involved both the central and peripheral interstitia. In this particular case, the treatment options were limited; however, early intervention with chemotherapy if the condition is diagnosed early can result in a rapid clinical response.
The differential diagnosis of pulmonary infiltrates in leukemia can include pulmonary infections, alveolar hemorrhage, pulmonary edema, induced pneumonitis and leukostasis.

Pulmonary leukemic infiltrate should be considered in all types of leukemia [10] but with stronger consideration during the pretreatment of leukemia or the terminal stage of the disease [6], when there is a progressive decline in respiratory status despite antibiotic therapy, bilateral interstitial infiltrates on imaging and laboratories showing high WBC counts with blasts accounting for >40% of the cells in the peripheral blood.

In conclusion, recognizing the diverse computed tomography patterns of pulmonary leukemic infiltration is paramount for selecting the appropriate therapy. This case represents a characteristic presentation of leukemic infiltrate in CMML that is similar to that in other types of leukemia.

ACKNOWLEDGMENTS
Special thanks are due to Pathology Associates (Fresno, CA) for providing the slide images.

CONFLICT OF INTEREST STATEMENT
Dr Fayed disclosed no relevant relationships regarding the content of this article. In terms of activities not related to the present article, Dr Fayed is a speaker for Insmed Inc.

FUNDING
None of the authors received any funding for this study.

ETHICS APPROVAL
Written consent was obtained from the family of the patient. None of the pictures had any content that could be used to identify the patient.

CONSENT
Written consent for the limited lung autopsy was obtained from the patient’s next of kin.

GUARANTOR
Mohamed Fayed is the guarantor of this article.

REFERENCES
1. Tefferi A, Longo DL. Less common hematologic malignancies. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J eds. Harrison’s Principles of Internal Medicine, 19th edn. New York, NY: McGraw-Hill, 2015, http://ac-cessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79732016.
2. Guru Murthy GS, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leuk Lymphoma 2017;58:1648–54.
3. Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989;64:1246–54.
4. Webb WR. Lymphoma and lymphoproliferative disease. In: Webb WR, Higgins CB eds. Thoracic Imaging: Pulmonary and Cardiovascular Radiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
5. Maile CW, Moore AV, Ulreich S, Putman CE. Chest radiographic-pathologic correlation in adult leukemia patients. Invest Radiol 1983;18:495–9.
6. Bashoura L, Eapen GA, Faiz SA. Pulmonary manifestations of lymphoma and leukemia. Clin Chest Med 2017;38:187–200.
7. Barcos M, Lane W, Gomez GA, et al. An autopsy study of 1206 acute and chronic leukemias (1958 to 1982). Cancer 1987;60:827–37.
8. Tanaka N, Matsumoto T, Miura G, et al. CT findings of leukemic pulmonary infiltration with pathologic correlation. Eur Radiol 2002;12:166–74.
9. Heyneman LE, Johkoh T, Ward S, Honda O, Yoshida S, Müller NL. Pulmonary leukemic infiltrates: high-resolution CT findings in 10 patients. AJR Am J Roentgenol 2000;174:517–21.
10. Viadana E, Bross ID, Pickren JW. An autopsy study of the metastatic patterns of human leukemias. Oncology 1978;35:87–96.